Horizon Kinetics Asset Management LLC Has $482,000 Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Horizon Kinetics Asset Management LLC raised its holdings in Kenvue Inc. (NYSE:KVUE) by 23.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 22,562 shares of the company’s stock after acquiring an additional 4,300 shares during the quarter. Horizon Kinetics Asset Management LLC’s holdings in Kenvue were worth $482,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Grove Bank & Trust increased its position in Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after acquiring an additional 947 shares during the period. Geneos Wealth Management Inc. acquired a new position in Kenvue in the 4th quarter valued at approximately $29,000. SRS Capital Advisors Inc. increased its position in Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after acquiring an additional 571 shares during the period. Fortitude Family Office LLC increased its position in shares of Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after buying an additional 777 shares during the period. Finally, Versant Capital Management Inc increased its position in shares of Kenvue by 300.8% during the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock worth $41,000 after buying an additional 1,441 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Up 2.6 %

Kenvue stock opened at $23.41 on Tuesday. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The firm has a market capitalization of $44.73 billion, a price-to-earnings ratio of 44.16, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. The firm’s fifty day moving average price is $21.89 and its two-hundred day moving average price is $22.40. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, equities research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.50%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is 154.72%.

Analyst Ratings Changes

KVUE has been the subject of several recent analyst reports. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. UBS Group decreased their price objective on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Royal Bank of Canada reiterated a “sector perform” rating and set a $24.00 price objective on shares of Kenvue in a research report on Monday, February 3rd. Piper Sandler increased their price objective on shares of Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research report on Monday, February 24th. Finally, Barclays decreased their price objective on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research report on Friday, January 17th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $23.75.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.